Koyfin Home > Directory > Health Care > Amphastar Pharma > Long-Term Debt

Amphastar Pharma Long-Term Debt Chart (AMPH)

Amphastar Pharma annual/quarterly Long-Term Debt from 2014 to 2018.
  • Amphastar Pharma Long-Term Debt for the quarter ending December 12, 2018 was $32m a -24.14% decrease of -8m year over year
  • Amphastar Pharma Long-Term Debt for the last 12 months ending December 12, 2018 was $32m a -24.14% decrease of -8m year over year
  • Amphastar Pharma Annual Long-Term Debt for 2018 was $32m a -24.25% decrease of -8m from 2017
  • Amphastar Pharma Annual Long-Term Debt for 2017 was $40m a 18.58% increase of 7m from 2016
  • Amphastar Pharma Annual Long-Term Debt for 2016 was $32m a 6.77% increase of 2m from 2015
Other Cash Flow Metrics:
  • Amphastar Pharma Cash Flow from Operations for the quarter ending September 09, 2018 was $16m a 38.12% increase of 6m year over year
  • Amphastar Pharma Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $2m a 389.71% increase of 8m year over year
  • Amphastar Pharma Total Revenue for the quarter ending December 12, 2018 was $90m a 34.89% increase of 31m year over year
View Chart On Koyfin

Quarterly AMPH Long-Term Debt Data

12/2018$32m
09/2018$33m
06/2018$34m
03/2018$40m
12/2017$40m
09/2017$42m
06/2017$40m
03/2017$31m
12/2016$32m
09/2016$34m

Annual AMPH Long-Term Debt Data

2018$32m
2017$40m
2016$32m
2015$30m
2014$36m
2013$10m